Tocilizumab is a humanized monoclonal antibody targeting the interleukin-6 receptor (IL-6R), binding to both soluble and membrane-bound forms. It inhibits IL-6-mediated pro-inflammatory signaling and is approved for rheumatoid arthritis, systemic juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, and severe COVID-19.